Recombinant Human Thrombopoietin Accelerates the Recovery of Platelet in Patients With Lower-Risk Myelodysplastic Syndrome: A Proof-of-Concept Study

Recombinant Human Thrombopoietin Accelerates the Recovery of Platelet in Patients With Lower-Risk Myelodysplastic Syndrome: A Proof-of-Concept Study

AimThe effect of recombinant human thrombopoietin (rhTPO) is largely unknown in lower-risk myelodysplastic syndrome (LR-MDS). This study aimed at investigating the safety and efficacy of rhTPO in patients with LR-MDS.MethodsLR-MDS patients receiving stanozolol (2 mg, t.i.d.) and supportive care alon...

Full description

Bibliographic Details
Main Authors: Yuan Yang, Zengwei Tang, Jiang Ji, Chen Yang, Miao Chen, Bing Han
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Oncology
Subjects:
lower-risk myelodysplastic syndrome
recombinant human thrombopoietin
hematologic response
adverse events
platelet response
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.721764/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.721764/full

Similar Items